caa a22 4500 465769071 CHVBK 20180323111924.0 cr unu---uuuuu 170327e19900301xx s 000 0 eng 10.1007/BF00155558 doi (NATIONALLICENCE)springer-10.1007/BF00155558 Current status of serotyping of Neisseria gonorrhoeae [Elektronische Daten] [P. Kohl, C. Ison, D. Danielsson, J. Knapp, D. Petzoldt] Protein I has become the basis of serotyping of N. gonorrhoeae. A panel of 12 anti-protein I monoclonal antibodies is supplied by Syva Company, Palo Alto, CA, through distributors for research purposes only. These distributors are responsible for storing the monoclonal antibodies, supplying research groups and training new users, particularly in the interpretation of coagglutination reactions. A European Workshop was held in Heidelberg, Federal Republic of Germany in July 1988 to discuss serotyping with these antibodies. The current uses of serotyping of N. gonorrhoeae include epidemiological studies, clinical purposes and surveillance of antibiotic resistance and plasmid carriage. Predominant serovars may be subtyped either by additional antibodies or with the use of another technique, such as auxotyping, determination of antibiotic sensitivities, plasmid analysis or genetic fingerprinting. Conversely, there is growing evidence that it may be appropriate to group certain serovars together. Data collected during prevalence studies could be combined with clinical information and an international data bank set up. This supposes a close future collaboration of all groups involved in the epidemiology of N. gonorrhoeae. Kluwer Academic Publishers, 1990 N. gonorrhoeae nationallicence Serotyping nationallicence Serovar nationallicence Kohl P. University-Hautklinik, Ruprechts-Karls-University Heidelberg, Voss-Str. 2, 6900, Heidelberg, Federal Republic of Germany aut Ison C. Dept. of Medical Microbiology, St. Mary's Hospital Medical School, London, England aut Danielsson D. Dept. of Clinical Microbiology and Immunology, Örebro Medical Center Hospital, Sweden aut Knapp J. Center for Infectious Diseases, Centers for Disease Control, Atlanta, GA, U.S.A. aut Petzoldt D. University-Hautklinik, Ruprechts-Karls-University Heidelberg, Voss-Str. 2, 6900, Heidelberg, Federal Republic of Germany aut European Journal of Epidemiology Kluwer Academic Publishers 6/1(1990-03-01), 91-95 0393-2990 6:1<91 1990 6 10654 https://doi.org/10.1007/BF00155558 text/html Onlinezugriff via DOI 1 brief-communication jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00155558 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kohl P. University-Hautklinik, Ruprechts-Karls-University Heidelberg, Voss-Str. 2, 6900, Heidelberg, Federal Republic of Germany aut NATIONALLICENCE 700 1- Ison C. Dept. of Medical Microbiology, St. Mary's Hospital Medical School, London, England aut NATIONALLICENCE 700 1- Danielsson D. Dept. of Clinical Microbiology and Immunology, Örebro Medical Center Hospital, Sweden aut NATIONALLICENCE 700 1- Knapp J. Center for Infectious Diseases, Centers for Disease Control, Atlanta, GA, U.S.A aut NATIONALLICENCE 700 1- Petzoldt D. University-Hautklinik, Ruprechts-Karls-University Heidelberg, Voss-Str. 2, 6900, Heidelberg, Federal Republic of Germany aut NATIONALLICENCE 773 0- European Journal of Epidemiology Kluwer Academic Publishers 6/1(1990-03-01), 91-95 0393-2990 6:1<91 1990 6 10654 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer